Aptevo Therapeutics Inc. (APVO)
| Market Cap | 5.37M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -23.72M |
| Shares Out | 18.51M |
| EPS (ttm) | -8.50 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,728,413 |
| Open | 0.264 |
| Previous Close | 0.250 |
| Day's Range | 0.224 - 0.326 |
| 52-Week Range | 0.138 - 10.800 |
| Beta | 5.06 |
| Analysts | Strong Buy |
| Price Target | 8.00 (+2,658.62%) |
| Earnings Date | Nov 7, 2024 |
About APVO
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company’s lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for APVO stock is "Strong Buy" and the 12-month stock price forecast is $8.0.
News
First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies
Potential to redefine frontline AML treatment being evaluated in clinic: Mipletamig, CD3 x CD123 bispecific, in combination with standard of care, offers a multi-mechanism strategy for potential impro...
First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial
Colon cancer patient achieved stable disease and remained on study for more than six months, breast cancer patient remained on study for more than 11 months Biomarker analysis confirms immune activati...
Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update
Company Achieves Milestones in Both Clinical Programs Initiates Mipletamig Phase 1b/2 Clinical Trial, "RAINIER," in Frontline Acute Myeloid Leukemia, Informed by Positive Dose Escalation Trial Results...
Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
SEATTLE, WA / ACCESSWIRE / September 18, 2024 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its pro...
Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
SEATTLE, WA / ACCESSWIRE / September 16, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its pro...
Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated
Aptevo's lead candidate APVO436 (mipletamig) to be evaluated in combination with standard of care venetoclax and azacitidine Company anticipates new data set to bolster existing compelling data report...
Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update
SEATTLE, WA / ACCESSWIRE / August 8, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprie...
Aptevo Therapeutics Announces Closing of $2.75 Million Offering
SEATTLE, WA / ACCESSWIRE / July 1, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprieta...
Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules
SEATTLE, WA / ACCESSWIRE / June 28, 2024 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its propriet...
Aptevo Participating in the BIO International Convention
SEATTLE, WA / ACCESSWIRE / June 3, 2024 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprieta...
Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA
Lecture to focus on engineering strategies applied to design safe and efficacious bispecific drug candidates, utilizing our proprietary platform technologies SEATTLE, WA / ACCESSWIRE / May 14, 2024 / ...
Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update
Heavily pre-treated breast cancer patient who achieved stable disease on study, remains on treatment for more than eleven months after entering the ALG.APV-527 Phase 1 trial with progressive disease a...
Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering
SEATTLE, WA / ACCESSWIRE / April 15, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprie...
Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
SEATTLE, WA / ACCESSWIRE / April 11, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprie...
Aptevo Therapeutics Provides Pipeline Update
Breast cancer patient who improved from a progressive disease diagnosis to an over nine-month sustained stable disease diagnosis has now successfully transitioned to a higher dose level, accessing the...
Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference
SEATTLE, WA / ACCESSWIRE / March 18, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprie...
Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update
Announces 1H24 Plan for Development of Lead Candidate APVO436 for the Treatment of Frontline Acute Myeloid Leukemia, Interim Results Expected Late 2H24 ALG.APV-527 Phase 1 Trial for the Treatment of M...
Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan
SEATTLE, WA / ACCESSWIRE / March 4, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), today announced that it will conduct a reverse stock split of its outstanding shares of c...
Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update
The Company's ALG.APV-527 Phase 1 Trial for the Treatment of Multiple Solid Tumors Continues to Progress Planning for APVO436 Phase 2 Trial Initiation in Both Relapsed/Refractory and Frontline AML Ong...
Aptevo to Present at Bio-Europe Conference
SEATTLE, WA / ACCESSWIRE / November 1, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its propr...
Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update
Positive Duration of Remission Data Adds to Growing Body of Clinical Evidence Supporting APVO436 for the Treatment of AML APVO436 Poised for Phase 2 Trial Initiation Later in 2H23 Company Completes $5...
Aptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offering
SEATTLE, WA / ACCESSWIRE / August 4, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical stage biotechnology company focused on developing novel immuno-oncology thera...
Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering
SEATTLE, WA / ACCESSWIRE / August 1, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical stage biotechnology company focused on developing novel immuno-oncology thera...
Aptevo Announces Positive Duration of Remission Data from Phase 1b Expansion Trial Evaluating the Bispecific APVO436 for AML
Phase 2 Trials in Relapsed/Refractory and Frontline Settings Planned, APVO436 to be administered in Combination with Emerging Standard of Care New Data Adds to Growing Body of Clinical Evidence in Sup...
Aptevo Therapeutics Reports 1Q23 Financial Results and Provides Business Update
Company Achieves Multiple Clinical and Preclinical Milestones and Raises $9.7 Million in Non-Dilutive Funding, Eliminates Balance Sheet Debt Introduces Novel Compound APVO711, Dual Mechanism of Action...